Takeda invests in celiac disease drug development with antibody licensing and conjugate development.
Takeda has signed a licensing deal with Innate Pharma to use a panel of antibodies to research and develop antibody-drug conjugates (ADCs) for celiac disease. In exchange for exclusive worldwide rights to whatever ADCs are developed using a selection of Innate’s antibodies, Takeda will give Innate a $5 million upfront payment with the potential for $410 million in milestones, plus royalties on net sales of any product resulting from the license.